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Accurate delivery of radiotherapy is a paramount component of providing safe oncological care. 
Margins are applied when planning radiotherapy to account for subclinical tumour spread, 
physiological movement and set-up error. Set-up error is unique to each radiotherapy institution 
and should be calculated for each organ site to ensure safe delivery of treatment. 
 
Aim and setting 
The aim of this study is to calculate the random and systematic set-up error for a cohort of patients 
with intracranial tumours treated with 3D Conformal Radiotherapy at the Department of Radiation 
Oncology, Groote Schuur Hospital, South Africa. After obtaining above mentioned data the ideal 
CTV-PTV expansion margin was calculated using published CTV-PTV expansion margin recipes. 
 
Patients and methods 
The Electronic Portal Images (EPID) of 20 patients who met the inclusion criteria were compared 
to their Digitally Reconstructed Radiograph (DRR). The set-up error for each patient was 
measured after which the random (s) and systematic (S) set-up error for the study group could be 
calculated. With both these values known the CTV-PTV expansion margin could be determined. 
 
Results 
The largest error was in the Superior/Inferior (SI) direction, followed by the Medial/Lateral (ML) 
direction and least in the Anterior/Posterior (AP) direction with 87.7%, 76.2% and 91.6% of the 
errors in the ML, SI and AP directions respectively being less than 3mm. 
There was no error larger than 5mm in the ML or AP direction with 6.1% of the SI error larger 
than 5mm. 
The random and systematic error in all three directions for this patient cohort were less than 
2mm conforming to acceptable standards of delivering safe radiotherapy. Using Stroom’s margin 





When treating patients with intracranial tumours at Groote Schuur Hospital the CTV-PTV 
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Accuracy of radiation delivery in radiotherapy is critical to ensure adequate coverage of a tumour 
and minimisation of normal tissue dose. It is important to establish uncertainties in dose 
distribution so that suitable treatment margins can be used for optimal therapy. 
 
The International Commission on Radiation Units and Measurements (ICRU) report 50 introduced 
the concept of a gross tumour volume (GTV), a clinical target volume (CTV) and a planning target 
volume (PTV)1 in radiotherapy. The GTV is classified as the gross demonstrable extent and 
location of the malignant growth.1 The CTV is a tissue volume that contains a demonstrable GTV 
or subclinical malignant disease that must be eliminated. The CTV is a clinical-anatomical concept 
and can be described as including structures with clinically suspected but unproved involvement.1,2 
The GTV almost always corresponds to those parts of the malignant growth where the tumour cell 
density is the highest, hence the importance of delivering adequate dose to the whole GTV.2 The 
PTV is a geometrical concept used for treatment planning and it is defined to select appropriate 
beam sizes and beam arrangements to ensure that the prescribed dose is actually delivered to the 
CTV.1,2 
 
Errors in radiotherapy can either be random or systematic. Systematic errors are a deviation that 
occur in the same direction and are of a similar magnitude for each fraction throughout the 
treatment course affecting the accuracy of the treatment. Random errors are a deviation that can 
vary in direction and magnitude during the treatment, affecting the precision of the treatment.3 
 
Positional uncertainties affect the dose distribution to target structures thus possibly compromising 
the clinical outcome of the treatment.4,5 Hurkmans et al. made a number of suggestions in their 
review article to reduce setup error, thus improving overall accuracy of treatment.6 Some of the 
suggestions were to perform portal images during a few treatment sessions over the course of 
treatment to ensure accuracy of treatment,7,8 to distinguish between systematic and random errors 
when analysing setup data,9,10 to use automated matching with portal images if a small 
measurement error is required11,12 and to use high-quality fixation devices, for example a 
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thermoplastic mask.13 
The amount of setup error is however unique to each institution. When determining the CTV-PTV 
margin, it is therefore recommended to use institution-specific data on setup error.14,15,16
2. Research methods and design
2.1. Patient group 
The study group consisted of 20 patients with intracranial tumours who were treated with 3D 
Conformal Radiotherapy (3DCRT) at the Department of Radiation Oncology, Groote Schuur 
Hospital, South Africa. 
The inclusion criteria were as follows: 
• Patients with intracranial tumours immobilised in a five-point thermoplastic mask on a S
frame from 2013 onwards using 3DCRT.
• Any intracranial tumour were included, regardless of histology, age of patient, gender of
patient or stage of disease.
• Patients with either radical or palliative intent could be included.
• Patients who had their electronic portal imaging done on day 1–3 and weekly thereafter as
per departmental protocol. A minimum of five sets of electronic portal images were
required for inclusion.
Exclusion criteria included any tumour that was extracranial or patients who were treated with any 
other modality than 3DCRT. 
2.2. Radiotherapy technique 
All patients were scanned in the supine position using a CT scanner (Toshiba) while being 
immobilised with a five-point thermoplastic mask attached to a couch overlay device. During 
immobilisation care was taken to ensure good imprint of the mask over the face and shoulders. 
 12 
The mask covered the entire head of the patient down to mid-shoulder. The isocentre was marked 
on the mask during simulation using wall-mounted lasers. During treatment the same reference 
system was used to ensure correct patient positioning. 
 
The CT images were reconstructed in 3 mm slices and then transferred to the treatment planning 
system (Varian Eclipse) for contouring by the physician. If available, MRI images were fused with 
the CT image to aid in contouring. The GTV and the organs at risk were delineated with a CTV 
margin added depending on the underlying tumour histology for that particular patient. A PTV 
was created by adding a 1 cm isotropic margin around the CTV. Planning risk volumes were 
created around critical structures such as the optic chiasm, brainstem and spinal cord. 
 
Treatment was delivered using one of two 6 MV Linear Accelerators (Varian Unique) using a 
3DCRT technique. Treatment lasted between 5 and 8 weeks depending on the diagnosis and intent 
of treatment. 
 
2.3. Image analysis 
 
Verification of position was done by obtaining orthogonal MV portal images on day 1–3 and 
weekly thereafter as per departmental protocol. Those images were compared to the digitally 
reconstructed radiograph (DRR) as constructed from their initial planning CT by using the auto-
matching function on the imaging software (Varian/ARIA Offline review). A total of 260 portal 
images (130 anterior-posterior [AP] and 130 lateral) were analysed and compared to 40 DRRs (20 
AP and 20 lateral) for the 20 patients. 
 
The inter-fractional setup error, which is the deviation between expected and actual patient 
position were measured in each direction. The measurements were registered in the three 




Deviations in the ML direction were measured using the AP images. Deviations in the SI direction 
were measured by evaluating both the AP and lateral images and in the AP direction only the 
lateral images were used. 
 
The intra-fractional setup error, which is the deviation in treatment that occurs during a single 
fraction of radiotherapy was ignored as they contribute very little to overall setup error in the head 
and neck area.6 
 
Rotational setup errors were measured by three-dimensional image analysis as part of the auto-
matching function on the imaging software. Out of plane rotational errors smaller than 3° in 
general do not cause an important deformation of the projected anatomy in portal images.6 
 
Gross errors as determined by departmental protocol (shifts larger than 5 mm in any direction) 
were corrected prior to treatment. 
 
All measurements were manually verified by the author by overlying the portal image over the 
DRR. Measured deviations were entered into a spreadsheet. 
 
2.5. Data analysis 
 
After evaluating studies who also calculated an institution-specific CTV-PTV margin a similar 
approach to data analysis was followed.17,18 
 
The setup errors in all three directions were used to calculate the random and systematic setup 
error for each individual patient and the patient group. The individual patient systematic setup 
error (μ) was calculated by taking the mean of the measured setup error for each imaged fraction 
in each direction. The individual patient random error was calculated by taking the standard 
deviation (SD) of the setup errors around the corresponding mean individual value. The group 
mean setup error (M) was calculated by taking the mean of the entire group setup error. The group 
systematic setup error (S) was derived by taking the SD of the individual mean setup error about 
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the group mean setup error. The group random error (s) was derived by taking the mean of all the 




Table 1 illustrates that 87.7%, 76.2% and 91.6% of the errors in the ML, SI and AP directions were 
less than 3 mm. The errors were largest in the SI direction, followed by the ML direction and 
smallest in the AP direction. There were no errors larger than 5 mm in the ML and AP direction 
and 6.1% of errors were larger than 5 mm in the SI direction. 
 










> −5 0  3 (2.3%) 0  
> −4 0  3 (2.3%) 0  
> −3 8 (6.2%) 16 (12.3%) 0  
> −2 20 (15.4%) 20 (15.4%) 4 (3.1%) 
> −1 35 (26.9%) 23 (17.7%)  20 (15.4%) 
0 23 (17.7%) 13 (10%) 42 (32.3%) 
> 1 19 (14.6%) 30 (23.1%) 35 (26.9%) 
> 2 17 (13.1%) 13 (10.0%) 18 (13.8%) 
> 3 6 (4.6%)  3 (2.3%) 9 (6.9%) 
> 4 2 (1.5%) 1 (0.8%) 2 (1.5%) 
> 5 0 5 (3.8%) 0 
The distribution of the setup errors in each of the directions is shown in graph format in Figure 1 




Source: Authors’ own work 
FIGURE 1: The distribution of setup errors in the medial-lateral direction. 
 
Source: Authors’ own work 


































Source: Authors’ own work. 
FIGURE 3: The distribution of set-up errors in the anterior-posterior direction. 
 
3.1. Clinical target volume-planning target volume margin 
 
The SD of the random and systematic population errors was calculated and is indicated as s and 
å. In some literature these errors are annotated as s random and s systematic but s and å are preferred 
to clearly distinguish between the two types of errors. 
 
As illustrated in Table 2 the systematic error ranges between 1.08 mm and 1.88 mm with the 
random error ranging between 0.73 mm and 1.18 mm. Errors in the SI direction are the largest 
followed by errors in the ML direction and least in the AP direction. 
 
TABLE 2: The systematic and random error as calculated in the medial-lateral, superior-inferior 




















Function Medial-lateral Superior-inferior Anterior-posterior 
Σ 1.42 mm 1.88 mm 1.08 mm 
s 0.82 mm 1.18 mm 0.73 mm 
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There are various margin recipes available to calculate the CTV-PTV margin. Most recipes 
ignore systematic errors and only use random errors. Examples would include Bel et al.’s recipe 
of 0.7s19 and Antolak et al.’s recipe of 1.65s.20 
 
As illustrated in Table 3, both of these result in much smaller margins as they underestimate the 
effect of systematic errors. The two main recipes incorporating systematic and random errors, are 
Stroom’s (2å + 0.7s)21 and Van Herk’s (2.5å + 0.7s)22, which result in much larger margins. 
Stroom’s recipe ensures on average that 99% of the target volume receives 95% of the prescribed 
dose or more. Van Herk’s recipe guarantees that 90% of patients in the population receive a 
minimum cumulative CTV dose of at least 95% of the prescribed dose. 
 
The importance of this concept is illustrated by the work done by Van Herk demonstrating to what 
extent random and systematic errors affect tumour control. A nomogram published by Van Herk 
shows tumour probability control loss as a function of margin, with random errors being half as 
important as systematic errors.23 
 







Hurkmans et al. compiled a summary of recent publications looking at the random and systematic 
setup errors in the three directions in the head and neck regions.6 Using this data, Hurkmans et al. 
Source Recipe Medial-lateral Superior-inferior Anterior-posterior 
Bel et al.  0.7σ 0.58 0.83 0.51 
Antolak & Rosen  1.65σ 1.36 1.95 1.21 
Stroom et al.  2Σ+ 0.7σ 3.42 4.58 2.67 
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determined that a SD of less than 2 mm for both the random and systematic error can be considered 
as ‘state of the art’.6
As demonstrated in Table 2 both random and systematic errors in all three directions are well 
within the 2 mm mark, thus conforming to accepted standards for good clinical practice. 
Hurkmans et al.’s study did not find any directional dependence in the systematic or random errors 
of the studies they reviewed. In our study the predominant error was in the SI direction. A possible 
explanation for this can be that the AP and lateral images were reviewed to determine the SI error 
which could have led to greater variability in the measurements. 
It would be unwise to utilise a margin recipe only using random errors to calculate a CTV-PTV 
expansion margin for safe radiotherapy. 
It was decided to use Stroom’s margin recipe for this study since it correlates with our institution’s 
clinical practice of ensuring that the entire target volume is encompassed by the 95% isodose line. 
Stroom’s recipe (2Σ + 0.7𝜎) suggests a margin of 5 mm for this patient cohort if CTV-PTV 
expansion is done in an isotropic fashion. 
Should the clinician decide to use anisotropic CTV-PTV expansion a margin of 5 mm in the SI 
direction, 3.5 mm in the ML direction and 3 mm in the AP direction can be considered. 
An additional area of research includes how Image Guided Radiotherapy (IGRT) techniques like 
Cone Beam CT can reduce CTV-PTV margin expansion. These technologies are increasingly 
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Please rate the manuscript on the following areas: 
1. Is the topic of current interest and appropriate for the Journal?:  
        Yes 
 
2. Importance?:  
        Moderate 
 
4. Purpose of Study?:  
        Defined 
 
5. Methods 
 Description, level of detail?:  
        Adequate 
 
6. Statistical Analysis 
 Description, level of detail?:  
        Adequate 
 
7. Data 
 Presentation, level of detail?:  
        Adequate 
 
8. Conclusion?:  
        Justified 
 
9. Timeliness?:  
        Current 
 
10. Overall Evaluation?:  
        Good 
 
11. Recommendation?:  
        Acceptable with minor revision 
 
COMMENTS TO AUTHORS 
 All comments you enter in this section will be provided verbatim to 
authors. 
13. Summary of major findings and shortcomings?:  
        I would have preferred to see some explanation as to why there was such 
discrepancy between the different dimensions. 
 
14. Major points that must be addressed? 
 Please provide a numbered list to facilitate responses with page and/or 
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line numbers and detailed information on specific recommendations.:  
        None 
 
15. Minor points or recommended revisions 
 Please provide numbered list to facilitate responses with page and/or line 
numbers and detailed information on specific recommendations.:  
        Line 63 - should read set-up data and not date? 
Line 114 - should read compared to and not compared against? 
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11. Recommendation?:  
        Acceptable with minor revision 
 
COMMENTS TO AUTHORS 
 All comments you enter in this section will be provided verbatim to 
authors. 
13. Summary of major findings and shortcomings?:  
        The authors present a well-executed determination of appropriate planning 
target volume margins for intracranial tumours at their institution.  The 
manuscript is generally well-written and the methods are appropriate.  Some 
elaboration in the Discussion would help to provide context for their 
results. 
 
14. Major points that must be addressed? 
 Please provide a numbered list to facilitate responses with page and/or 
line numbers and detailed information on specific recommendations.:  
        None 
 
15. Minor points or recommended revisions 
 Please provide numbered list to facilitate responses with page and/or line 
numbers and detailed information on specific recommendations.:  
        1. Abstract: Recommend describing resultant margin estimate in the Results 
instead of the Conclusions 
2. Page 1, paragraph 1: ICRU report 58 describes interstitial brachytherapy 
reporting.  Recommend referencing ICRU 50 or 62, which are external beam 
guidelines, instead. 
3. Page 2, paragraph 8:  The reference to “films” is confusing.  The 
text up to this point suggests the images are all electronic. 
4. Page 3, paragraph 5: Recommend a reference for these methods. 
5. Page 3, paragraph 5: “mi” is not a conventionally used symbol for 
these quantities.  The authors may be referring to the Greek letter “mu” 
7. Page 12, Table 3: Should be “Bel” instead of “Ber” 
8. Page 12, Table 3: Recommend adding van Herk margin recipe to Table 3 
since it is discussed in the immediately preceding paragraph 
9. Page 13: The authors should discuss how did they selected the Stroom 
recipe over van Herk recipe. 
10. Page 13: The authors should discuss if they have a hypothesis for why 










Attached hereto is a copy of the Excel spreadsheet used for this study. Information captured on the 
datasheet includes:  
1) The patients’ RT number 
2) Diagnosis  
3) Stage  
4) Location of their tumour 
5) Sex of the patient 
6) Age of the patient 
7) Fractionation used for their treatment 
8) Intent of their treatment 
9) Start and end date of their treatment 
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